Human Genome agrees to GlaxoSmithKline takeover Associated Press Copyright 2012 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed. Updated 03:19 p.m., Monday, July 16, 2012 N.J. (AP) — U.K. drug maker GlaxoSmithKline has secured its takeover of longtime partner Human Genome Sciences after agreeing to pay more, a move to expand GSK's drug portfolio in crucial areas: biologic drugs and treatments for the hundreds of millions of people with diabetes and heart disease. Most other treatments either simply reduce inflammation and pain, take months to improve symptoms or can cause a host of significant side effects. Benlysta, a biologic drug produced in living cells, is meant to block or limit immune system attacks on the patient's cells and tissue, which cause inflammation and damage to organs. The deal also brings GSK two promising experimental drugs in late-stage human testing, albiglutide for Type 2 diabetes and darapladib, a heart drug being tested for prevention of stroke and heart attack. GSK's higher offer followed news of positive results on albiglutide from a study of cardiac safety — an issue that's now crucial for winning U.S.